Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor. [electronic resource]
Producer: 20040909Description: 5355-62 p. digitalISSN:- 0008-5472
- Animals
- Antibodies, Monoclonal -- administration & dosage
- Antibodies, Monoclonal, Humanized
- Antineoplastic Combined Chemotherapy Protocols -- therapeutic use
- Apoptosis -- drug effects
- Carcinoma, Non-Small-Cell Lung -- drug therapy
- Carcinoma, Squamous Cell -- drug therapy
- Cell Division -- drug effects
- Cetuximab
- Enzyme Inhibitors -- pharmacology
- ErbB Receptors -- antagonists & inhibitors
- Erlotinib Hydrochloride
- Female
- Flow Cytometry
- Gefitinib
- Head and Neck Neoplasms -- drug therapy
- Humans
- Immunoblotting
- Lung Neoplasms -- drug therapy
- Male
- Mice
- Mitogen-Activated Protein Kinases -- metabolism
- Phosphorylation -- drug effects
- Proliferating Cell Nuclear Antigen -- metabolism
- Prostatic Neoplasms -- drug therapy
- Protein Serine-Threonine Kinases -- metabolism
- Protein-Tyrosine Kinases -- antagonists & inhibitors
- Proto-Oncogene Proteins -- metabolism
- Proto-Oncogene Proteins c-akt
- Quinazolines -- administration & dosage
- Transplantation, Heterologous
- Tumor Cells, Cultured
No physical items for this record
Publication Type: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.